Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2012

01-08-2012 | Original Article

The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: effects of long-term interdisciplinary therapy

Authors: Raquel M. S. Campos, Aline de Piano, Patrícia L. da Silva, June Carnier, Priscila L. Sanches, Flávia C. Corgosinho, Deborah C. L. Masquio, Marise Lazaretti-Castro, Lila M. Oyama, Cláudia M. O. Nascimento, Lian Tock, Marco Túlio de Mello, Sergio Tufik, Ana R. Dâmaso

Published in: Endocrine | Issue 1/2012

Login to get access

Abstract

To investigate the role of pro- and anti-inflammatory adipokines in the bone metabolism of non-alcoholic fatty liver disease (NAFLD) obese adolescents as well as the effects of long-term interdisciplinary therapy on metabolic-related risk factors. Forty post-puberty obese adolescents were randomly assigned into two groups: (1) NAFLD group and (2) non-NAFLD group (diagnosis by ultrasonography) and submitted to a weight loss therapy. Body composition was analyzed by air displacement plethysmography, bone mineral density (BMD) and content by dual-energy X-ray absorptiometry, blood samples were collected to measure lipid profile, hepatic enzymes, and adipokines. Leptin and adiponectin concentrations were measured by ELISA. A decrease in total body mass, BMI, body fat, visceral and subcutaneous fat, insulin concentration, HOMA-IR, total cholesterol and an increase in lean body mass were observed in both groups after therapy. It was found positive correlation between the Δ BMD and the Δ fat mass (%) (r = 0.31, P = 0.01) and negative correlations between Δ BMC with Δ HOMA-IR (r = −0.34, P = 0.02) and Δ HOMA-IR with Δ leptin (r = −0.34, P = 0.02). In addition, increased levels of adiponectin and reduction in leptin concentrations were observed in NAFLD group. In the simple regression analysis, the HOMA-IR was an independent predictor changes in BMC in total obese adolescents and in the non-NAFLD group. One year of interdisciplinary weight loss therapy for obese adolescents with or without NAFLD, could regulate bone mineral metabolism as result of an increased BMC and improved inflammatory state.
Literature
1.
N.K. Pollock, P.J. Bernard, B. Gutin, C.L. Davis, H. Zhu, Y. Dong, Adolescent obesity, bone mass and cardiometabolic risk factors. J. Pediatr. 158, 727–734 (2011)PubMedCrossRef
2.
L.E. Polgreen, Keeping a broad approach to managing pediatric bone disease. J. Pediatr. Gastroenterol. Nutr. 51, 128–129 (2010)PubMedCrossRef
3.
P. Dimitri, N. Bishop, J.S. Walsh, R. Eastell, Obesity is a risk factor for fracture in children but is protective against fracture in adults: a paradox. Bone 50(2), 457–466 (2011)PubMedCrossRef
4.
M.B. Leonard, J. Shults, B.A. Wilson, A.M. Tershakovec, B.S. Zemel, Obesity during childhood and adolescence augments bone mass and bone dimensions. Am. J. Clin. Nutr. 80, 514–523 (2002)
5.
E. Rocher, C. Chappard, C. Jaffre, C.L. Benhamou, D. Courteix, Bone mineral density in prepubertal obese and control children: relation to body weight, lean mass, and fat mass. J. Bone Miner. Metab. 26, 73–78 (2008)PubMedCrossRef
6.
D.K. Hwang, H.J. Choi, The relationship between low bone mass and metabolic syndrome in Korean women. Osteoporos. Int. 21, 425–431 (2010)PubMedCrossRef
7.
W.L. do Prado, A. de Piano, M. Lazaretti-Castro, M.T. de Mello, S.G. Stella, S. Tufik et al., Relationship between bone mineral density, leptin and insulin concentration in Brazilian obese adolescents. J. Bone Miner. Metab. 27, 613–619 (2009)PubMedCrossRef
8.
A. de Piano, L. Tock, J. Carnier, D. Foschini, P.L. Sanches, F.A. Corrêa et al., The role of nutritional profile in the orexigenic neuropeptide secretion in nonalcoholic fatty liver disease obese adolescents. Eur. J. Gastroenterol. Hepatol. 22, 557–563 (2010)PubMedCrossRef
9.
A. de Piano, W.L. Prado, D.A. Caranti, K.O. Siqueira, S.G. Stella, M. Lofrano et al., Metabolic and nutritional profile of obese adolescents with nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr. 44, 446–452 (2007)PubMedCrossRef
10.
A. de Piano, W.L. Prado, D.A. Caranti, K.O. Siqueira, S.G. Stella, M. Lofrano et al., Relationship between nonalcoholic fatty liver disease prevalence and visceral fat in obese adolescents. Dig. Liver Dis. 40, 132–139 (2008)PubMedCrossRef
11.
R. Wang, Q. Lu, J. Feng, F. Yin, C. Qin, B. Liu, Coexistence of non-alcoholic fatty liver disease with elevated alanine aminotransferase is associated with insulin resistance in young Han males. Endocrine 41(1), 70–75 (2011)PubMedCrossRef
12.
E.A. Roberts, Pediatric nonalcoholic fatty liver disease (NAFLD): a “growing” problem? J. Hepatol. 46, 113–142 (2007)CrossRef
13.
E. Scorletti, P.C. Calder, C.D. Byrne, Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine 40(3), 332–343 (2011)PubMedCrossRef
14.
O. Pirgon, H. Bilgin, I. Tolu, D. Odabas, Correlation of insulin sensitivity with bone mineral status in obese adolescents with non-alcoholic fatty liver disease. Clin. Endocrinol. (Oxf) 75, 189–195 (2011)CrossRef
15.
I. Tasci, G. Erdem, A. Sonmez, T. Dogru, C.N. Ercin, Hepatic steatosis, visceral adiposity, insulin resistance, adiponectin, and inflammation. Metabolism 58, 141 (2009)PubMedCrossRef
16.
V. Nobili, A. Reale, A. Alisi, G. Morino, I. Trenta, M. Pisani et al., Elevated serum ALT in children presenting to the emergency unit: relationship with NAFLD Dig. Liver Dis. 41, 749–752 (2009)CrossRef
17.
D.A. Rubin, R.G. McMurray, J.S. Harrell, A.C. Hackney, D.E. Thorpe, A.M. Haqq, The association between insulin resistance and cytokines in adolescents: the role of weight status and exercise. Metabolism 57, 683–690 (2008)PubMedCrossRef
18.
T. Yatagai, S. Nagasaka, A. Taniguchi, M. Fukushima, T. Nakamura, A. Kuroe, Y. Nakai, S. Ishibashi, Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 52, 1274–1278 (2003)PubMedCrossRef
19.
A.R. de Dâmaso, A. Piano, P.L. Sanches, F. Corgosinho, L. Tock, L.M. Oyama et al., Hyperleptinemia in obese adolescents deregulates neuropeptides during weight loss. Peptides 32, 1384–1391 (2011)PubMedCrossRef
20.
S. Blüher, C.S. Mantzoros, Leptin in humans: lessons from translational research. Am. J. Clin. Nutr. 89, 991S–997S (2009)PubMedCrossRef
21.
M.H. Tschöp, D.Y. Hui, T.L. Horvath, Diet-induced leptin resistance: the heart of the matter. Endocrinology 148, 921–923 (2007)PubMedCrossRef
22.
G.D. Norata, S. Raselli, L. Grigore, K. Garlaschelli, E. Dozio, P. Magni, A.L. Catapano, Leptin: adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke 38, 2844–2846 (2007)PubMedCrossRef
23.
J.M. Tanner, R.H. Whithouse, Clinical longitudinal standards for height, weight velocity and stages of puberty. Arch. Dis. Child. 51, 170–179 (1976)PubMedCrossRef
24.
B. Gutin, L. Ramsey, P. Barbeau, W. Cannady, M. Ferguson, M. Litaker et al., Plasma leptin concentrations in obese children: changes during 4-mo periods with and without physical training. Am. J. Clin. Nutr. 69, 388–394 (1996)
25.
J.B. Schwimmer, R. Deutsch, J.B. Rauch, C. Behling, R. Newbury, J.E. Lavine, Obesity, insulin resistance, and other clinicopathological correlates of pediatrics nonalcoholic fatty liver disease. J. Pediatr. 143, 500–505 (2003)PubMedCrossRef
26.
E. Black, L. Petersen, M. Kreutzer, S. Toubro, T.I. Sørensen, O. Pedersen et al., Fat mass measured by DXA varies with scan mode. Obes. Res. 10, 69–77 (2002)PubMedCrossRef
27.
F.F. Ribeiro-Filho, A.N. Faria, S. Azjen, M.T. Zanella, S.R. Ferreira, Methods of estimation of visceral fat: advantages of ultrasonography. Obes. Res. 11, 1488–1494 (2003)PubMedCrossRef
28.
N. Sabir, Y. Sermez, S. Kazil, M. Zencir, Correlation of abdominal fat accumulation and liver steatosis: importance of ultrasonographic and anthropometric measurements. Eur. J. Ultrasound. 14, 121–128 (2001)PubMedCrossRef
29.
S. Saadeh, Z.M. Younossi, E.M. Remer, T. Gramlich, J.P. Ong, M. Hurley et al., The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123, 745–750 (2002)PubMedCrossRef
30.
S.P. Murphy, M.I. Poos, Dietary reference intakes: summary of applications in dietary assessment. Public Health Nutr. 5, 843–849 (2002)PubMedCrossRef
31.
A.R. Dâmaso, A. de Piano, L. Tock et al., Nutritional and clinical strategies on the prevention and treatment of NAFLD and metabolic syndrome, in Nutrition, diet therapy and the liver, 1st edn., ed. by V.R. Preedy, R. Srirajaskanthan, R. Lakshman, R.R. Watson (Taylor & Francis Group, Boca Raton, 2009), pp. 113–130CrossRef
32.
C.E.Garber, B. Blissmer, M.R. Deschenes, B.A. Franklin, M.J. Lamonte, I.M. Lee et al., American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med. Sci. Sports Exerc. 43, 1334–1359 (2011)
33.
W.J. Kraemer, M.S. Fragala, Personalize it: program design in resistance training. ACSM’S Health Fit. J. 10, 7–17 (2006)CrossRef
34.
S. Freitas, C.S. Lopes, W. Coutinho, J.C. Appolianario, Tradução e adaptação para o português da Escala de Compulsão Alimentar Periódica. Rev. Bras. Psiquiatr. 23, 215–220 (2001)CrossRef
35.
T.A. Cordás, P.B. Hochgraf, O ‘‘BITE’’ Instrumento para avaliação da Bulimia nervosa: Versão para o português. J. Bras. Psiquiatr. 42, 141–144 (1993)
36.
J. Gormally, S. Black, S. Daston, D. Rardin, The assessment of binge eating severity among obese persons. Addict. Behav. 7, 47–55 (1982)PubMedCrossRef
37.
M. Henderson, C.P.L. Freeman, A self-rating scale for bulimia. The BITE. Br. J. Psychiatry 50, 18–24 (1987)CrossRef
38.
P. Isnard, G. Michel, M.L. Frelut, G. Vila, B. Falissard, W. Naja, Binge eating and psychopathology in severely obese adolescents. Int. J. Eat. Disord. 34, 235–243 (2003)PubMedCrossRef
39.
C.T. Rubin, L.E. Lanyon, Regulation of bone mass by mechanical strain magnitude. Calcif. Tissue Int. 37, 411–417 (1985)PubMedCrossRef
40.
L.E. Lanyon, C.T. Rubin, Static vs. dynamic loads as an influence on bone remodelling. J. Biomech. 17, 897–905 (1984)PubMedCrossRef
41.
T. Notomi, Y. Okazaki, N. Okimoto, S. Saitoh, T. Nakamura, M. Suzuki, A comparison of resistance and aerobic training for mass, strength and turnover of bone in growing rats. Eur. J. Appl. Physiol. 83, 469–474 (2000)PubMedCrossRef
42.
G. Radetti, W. Kleon, J. Stuefer, K. Pittschieler, Non-alcoholic fatty liver disease in obese children evaluated by magnetic resonance imaging. Acta Paediatr. 95, 833–837 (2006)PubMedCrossRef
43.
D.F. Chan, A.M. Li, W.C. Chu, M.H. Chan, E.M. Wong, E.K. Liu et al., Hepatic steatosis in obese Chinese children. Int. J. Obes. Relat. Metab. Disord. 28, 1257–1263 (2004)PubMedCrossRef
44.
N.K. Lee, H. Sowa, E. Hinoi, M. Ferron, J.D. Ahn, C. Confavreux et al., Endocrine regulation of energy metabolism by the skeleton. Cell 130, 456–469 (2007)PubMedCrossRef
45.
A. Afghani, M.L. Cruz, M.I. Goran, Impaired glucose tolerance and bone mineral content in overweight Latino children with a family history of type 2 diabetes. Diabetes Care 28, 372–378 (2005)PubMedCrossRef
46.
N.K. Pollock, P.J. Bernard, K. Wenger, S. Misra, B.A. Gower, J.D. Allison et al., Lower bone mass in prepubertal overweight children with pre-diabetes. J. Bone Miner. Res. 25, 2484–2493 (2010)CrossRef
47.
P. McNair, S. Madsbad, M.S. Christensen, C. Christiansen, O.K. Faber, C. Binder et al., Bone mineral loss in insulin-treated diabetes mellitus: studies on pathogenesis. Acta Endocrinol. 90, 463–472 (1979)PubMed
48.
T. Miyata, K. Notoya, K. Yoshida, K. Horie, K. Maeda, K. Kurokawa et al., Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J. Am. Soc. Nephrol. 8, 260–270 (1997)PubMed
49.
J. Argente, N. Caballo, V. Barrios, J. Pozo, M.T. Muñoz, J.A. Chowen et al., Multiple endocrine abnormalities of the growth hormone and insulin like growth factor axis in prepubertal children with exogenous obesity: effect of short- and long-term weight reduction. J. Clin. Endocrinol. Metab. 82, 2076–2083 (1997)PubMedCrossRef
50.
E. Hinoi, N. Gao, D.Y. Jung, V. Yadav, T. Yoshizawa, M.G. Myers Jr. et al., The sympathetic tone mediates leptin’s inhibition of insulin secretion by modulating osteocalcin bioactivity. J. Cell Biol. 183, 1235–1242 (2008)PubMedCrossRef
51.
M.W. Hamrick, S.L. Ferrari, Leptin and the sympathetic connection of fat to bone. Osteoporos. Int. 19, 905–912 (2008)PubMedCrossRef
52.
A. Martin, V. David, L. Malaval, M.H. Lafage-Proust, L. Vico, T. Thomas, Opposite effects of leptin on bone metabolism: a dose-dependent balance related to energy intake and insulin-like growth factor-I pathway. Endocrinology 148, 3419–3425 (2007)PubMedCrossRef
53.
Y. Okamoto, S. Kihara, N. Ouchi, M. Nishida, Y. Arita, M. Kumada et al., Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106(22), 2767–2770 (2002)PubMedCrossRef
54.
R. Ouedraogo, Y. Gong, B. Berzins, X. Wu, K. Mahadev, K. Hough et al., Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J. Clin. Invest. 117(6), 1718–1726 (2007)PubMedCrossRef
55.
A.R. Nawrocki, S.M. Hofmann, D. Teupser, J.E. Basford, J.L. Durand, L.A. Jelicks et al., Lack of association between adiponectin levels and atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 30(6), 115911–115965 (2010)CrossRef
56.
R.S. Lindsay, T. Funahashi, R.L. Hanson, Y. Matsuzawa, S. Tanaka, P.A. Tataranni et al., Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360(9326), 57–58 (2002)PubMedCrossRef
57.
C. Snehalatha, B. Mukesh, M. Simon, V. Viswanathan, S.M. Haffner, A. Ramachandran, Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care 26(12), 3226–3229 (2003)PubMedCrossRef
58.
S. Li, H.J. Shin, E.L. Ding, R.M. van Dam, Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302(2), 179–188 (2008)CrossRef
59.
N. Klöting, M. Fasshauer, A. Dietrich, P. Kovacs, M.R. Schön, M. Kern et al., Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab. 299(3), E506–E515 (2010)PubMedCrossRef
60.
V.Z. Rocha, E.J. Folco, Inflammatory concepts of obesity. Int. J. Inflam. 2011, 529061 (2011)PubMed
61.
A.R. Dâmaso, W.L. do Prado, A. de Piano, L. Tock, D.A. Caranti, M.C. Lofrano et al., Relationship between nonalcoholic fatty liver disease prevalence and visceral fat in obese adolescents. Dig. Liver Dis. 40(2), 132–139 (2008)PubMedCrossRef
Metadata
Title
The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: effects of long-term interdisciplinary therapy
Authors
Raquel M. S. Campos
Aline de Piano
Patrícia L. da Silva
June Carnier
Priscila L. Sanches
Flávia C. Corgosinho
Deborah C. L. Masquio
Marise Lazaretti-Castro
Lila M. Oyama
Cláudia M. O. Nascimento
Lian Tock
Marco Túlio de Mello
Sergio Tufik
Ana R. Dâmaso
Publication date
01-08-2012
Publisher
Springer US
Published in
Endocrine / Issue 1/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9613-3

Other articles of this Issue 1/2012

Endocrine 1/2012 Go to the issue

Meta-Analysis

Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis

Original Article

The relationship between high-sensitivity C-reactive protein and ApoB, ApoB/ApoA1 ratio in general population of China

Editorial

Saturated free fatty acids: islet β cell “stressERs”

Original Article

Study of the leptin levels and its gene polymorphisms in patients with idiopathic short stature and growth hormone deficiency

Original Article

Subclinical hypercortisolism and CT appearance in adrenal incidentalomas: a multicenter study from Southern Sweden

Editorial

Subclinical hypercortisolism: debatable or visible on the lightbox?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits